FreshPatents.com Logo
Enter keywords:  

Track companies' patents here: Public Companies RSS Feeds | RSS Feed Home Page
Popular terms

[SEARCH]

Follow us on Twitter
twitter icon@FreshPatents

Web & Computing
Cloud Computing
Ecommerce
Search patents
Smartphone patents
Social Media patents
Video patents
Website patents
Web Server
Android patents
Copyright patents
Database patents
Programming patents
Wearable Computing
Webcam patents

Web Companies
Apple patents
Google patents
Adobe patents
Ebay patents
Oracle patents
Yahoo patents

[SEARCH]

Factor patents



      
           
This page is updated frequently with new Factor-related patent applications. Subscribe to the Factor RSS feed to automatically get the update: related Factor RSS feeds. RSS updates for this page: Factor RSS RSS


Date/App# patent app List of recent Factor-related patents
09/04/14
20140249312
 [1,3]dioxolo[4,5-g]quinoline-6(5h)thione and [1,3]dioxolo[4,5-g][1,2,4]triazolo[1,5-a]quinoline derivatives as inhibitors of the late sv40 factor (lsf) for use in treating cancer patent thumbnail[1,3]dioxolo[4,5-g]quinoline-6(5h)thione and [1,3]dioxolo[4,5-g][1,2,4]triazolo[1,5-a]quinoline derivatives as inhibitors of the late sv40 factor (lsf) for use in treating cancer
The present invention relates generally to [1,3]dioxolo[4,5-g]quinoline-6(5h)thione and [1,3]dioxolo[4,5-g][1,2,4]triazolo[1,5-a]quinoline derivatives and/or compositions for use in inhibiting, preventing and/or treating cancer, e.g. Hepatocellular carcionoma (hcc).
09/04/14
20140249234
 Compositions and methods for restoring the stratum corneum and treating dermatological diseases patent thumbnailCompositions and methods for restoring the stratum corneum and treating dermatological diseases
The present invention provides methods of treating humans and animals with terpenes and terpenoids in order to restore the stratum granulosum and stratum corneum and treat a dermatological disease, such as, for instance atopic dermatitis. More specifically it provides terpenes and terpenoids such as monoterpenoids, sesquiterpenes and norisoprenoids as ingredients that work to restore and thicken the stratum granulosum and stratum corneum and treat a dermatological disease.
09/04/14
20140249219
 Anti-obesity potential of calebin a patent thumbnailAnti-obesity potential of calebin a
The present invention discloses the potential of calebin a in inhibiting adipogenesis and applications thereof in obesity management. The present invention elucidates the potential of calebin a to favorably modulate biochemical markers associated with obesity.
09/04/14
20140249209
 Methods for the treatment and prevention of liver disease patent thumbnailMethods for the treatment and prevention of liver disease
The presently disclosed invention is directed to the discovery that hepatocyte nuclear factor 4 alpha (hnf4α; also known as nr2a1), a transcription factor, reverses hepatocyte dysfunction in an animal model of cirrhosis, resulting in improvement in hepatic function, treatment of cirrhosis, and prolonged survival.. .
09/04/14
20140249086
 Method for improving the stability of purified factor viii after reconstitution patent thumbnailMethod for improving the stability of purified factor viii after reconstitution
The present invention relates to a method for increasing the stability of a factor viii molecule after purification, lyophilization and reconstitution, comprising preventing proteolytic cleavage of the factor viii molecule into a first fragment comprising essentially the a1 domain and the a2 domain and a second fragment comprising essentially the a3 domain, the c1 domain and the c2 domain throughout manufacturing of the factor viii molecule. The invention further pertains to a method for improving the bioavailability of factor viii after intravenous and non-intravenous injection..
09/04/14
20140248653
 Method for selecting mevalonate synthesis modulators using cells derived from human pluripotent cells patent thumbnailMethod for selecting mevalonate synthesis modulators using cells derived from human pluripotent cells
A method for selecting pharmaceutical compounds affecting mevalonate or cholesterol, having a step for putting into contact with the pharmaceutical compounds to be tested, cells of the msc type obtained by a method for producing cells of the msc type from human pluripotent cells or from induced stem cells, including a step for cultivating human pluripotent cells or induced stem cells in a culture medium having the steps of: 1) one or more growth factors selected from fgfs, hgf, pdgfs, egf, herugulins and vegfs, and 2) one or more antioxidants selected from ascorbic acid and its derivatives, vitamin e and n-acetylcysteine.. .
09/04/14
20140248637
 Composition for diagnosis of lung cancer and diagnosis kit of lung cancer patent thumbnailComposition for diagnosis of lung cancer and diagnosis kit of lung cancer
Disclosed is as a biomarker useful in early diagnosis of lung cancer, at least one protein selected from the group including quescin-sulfhydryl oxidase 1, fibrillin-1, isoform a of lamin-a/c, latent-transforming growth factor beta-binding protein 2, galectin-1, highly similar to dickkopf-related protein 3, isoform a1-b of heterogeneous nuclear ribonucleoprotein a1, 14-3-3 protein epsilon, stanniocalcin-2, cystatin-c, isoform 1 of connective tissue growth factor, profilin-1, isoform 1 of extracellular matrix protein 1, histone h2b type 2-e, kinesin-like protein kif26a, zinc finger protein 516, and isoform 1 of a-kinase anchor protein 9.. .
09/04/14
20140248364
 Divalent-metal coated nanoparticles for delivery of compositions into the central nervous system by nasal insufflation patent thumbnailDivalent-metal coated nanoparticles for delivery of compositions into the central nervous system by nasal insufflation
The compositions and methods of the disclosure particularly target the divalent metal transporter expressed on olfactory nerve terminals to transport divalent cation-coated or cation-containing nanoparticles to all regions of brain. It has been found that such divalent cation-containing nanoparticles, including those nanoparticles comprising manganese have affinity for the metal transport receptor proteins.
09/04/14
20140248302
 Recombinant proteins and their therapeutic uses patent thumbnailRecombinant proteins and their therapeutic uses
A recombinant protein expressing one or more human growth factors, tumor antigens, and/or receptors or epitopes thereof on or within an immunogenic expression creating a recombinant protein in which one or more epitopes are presented on the surface of the sequence in their natural configuration. The growth factor, tumor antigen, and/or receptor, sequence(s) may be expressed within the encoding sequence at appropriate internal positions or at the termini as single expressions or as two or more tandem repeats..
09/04/14
20140248259
 Compositions and methods for modulating hemostasis patent thumbnailCompositions and methods for modulating hemostasis
Factor x/xa variants and methods of use thereof are disclosed.. .
09/04/14
20140246753
High quality factor inductor implemented in wafer level packaging (wlp)
Some novel features pertain to a first example provides a semiconductor device that includes a printed circuit board (pcb), asset of solder balls and a die. The pcb includes a first metal layer.
09/04/14
20140246551
Adjustable holder for devices
Disclosed is an adjustable holder for devices with a simplified design for accommodating devices of various form factors and shapes. The adjustable holder comprises at least a pair of offset, generally parallel arms that are slidable within corresponding openings of a support in order to adjust the arms and fixedly position the arms at varying distances relative to the support.
09/04/14
20140246036
Transcription factors that regulate nicotine biosynthesis in tobacco
The present invention provides nucleic acids encoding transcription factors and methods of using these nucleic acids to modulate nicotine production in plants and to produce plants having modulated nicotine production.. .
08/28/14
20140245028
System and method for temperature driven selection of voltage modes in a portable computing device
Various methods and systems for minimum supply voltage level selection in a portable computing device (“pcd”) are disclosed. It is an advantage of the various embodiments that pcd designers may close timing at a certain minimum supply voltage and operating temperature threshold that is higher than the lowest end of the main operating temperature range within which the pcd must function.
08/28/14
20140244886
Controller for facilitating out of band management of rack-mounted field replaceable units
A system for the management of rack-mounted field replaceable units (frus) that affords the enhanced availability and serviceability of frus provided by blade-based systems but in a manner that accommodates different types of frus (e.g., in relation to form factors, functionality, power and cooling requirements, and/or the like) installed within a rack or cabinet.. .
08/28/14
20140244881
Computing rack-based virtual backplane for field replaceable units
A system for the management of rack-mounted field replaceable units (frus) that affords the enhanced availability and serviceability of frus provided by blade-based systems but in a manner that accommodates different types of frus (e.g., in relation to form factors, functionality, power and cooling requirements, and/or the like) installed within a rack or cabinet.. .
08/28/14
20140244311
Protecting against data loss in a networked computing environment
An approach for protecting (e.g., insuring) against data loss (e.g., due to sla failures) in a networked computing environment (e.g., a cloud computing environment) is provided. In a typical embodiment, a risk table is created that associates cloud/solution providers with a corresponding risk factor and a cost of insuring the providers based on the risk factors.
08/28/14
20140243398
Irs modulators
This invention is directed to a general method for the chronic treatment, potential cure, or prevention of various metabolic and related diseases in people, including diabetes, by modulating irs2 activity in cells and tissues in the body. Irs1 and irs2 are part of the insulin or insulin-like growth factor signaling pathway.
08/28/14
20140243339
Combinations vegf(r) inhibitors and hepatocyte growth factor (c-met) inhibitors for the treatment of cancer
This invention is in the field of pharmaceutical agents and specifically relates to compounds, compositions, uses and methods for treating cancer, by combining vegf(r) inhibitors and inhibitors of hgf/sf:c-met.. .
08/28/14
20140243324
Use of hematopoietic growth factor mimetics
The present invention relates to uses of small molecule mimetics of hematopoietic growth factors. In particular the present invention relates to uses of small molecule mimetics of erythropoietin..
08/28/14
20140243266
Uses and methods for modulating bile acid homeostasis and treatment of bile acid disorders and diseases
The invention relates to variants and fusions of fibroblast growth factor 19 (fgf19), variants and fusions of fibroblast growth factor 21 (fgf21), fusions of fibroblast growth factor 19 (fgf19) and/or fibroblast growth factor 21 (fgf21), and variants or fusions of fibroblast growth factor 19 (fgf19) and/or fibroblast growth factor 21 (fgf21) proteins and peptide sequences (and peptidomimetics), having one or more activities, such as bile acid homeostasis modulating activity, and methods for and uses in treatment of bile acid and other disorders.. .
08/28/14
20140243264
Methods of treatment for retinal diseases
The present invention provides methods of treating a retinal disorder comprising administering an effective amount of a neurotrophic factor to a subject having the retinal disorder. The neurotrophic factors useful in the invention include mesencephalic astrocyte-derived neurotrophic factor (manf) and conserved dopamine neurotrophic factor (cdnf).
08/28/14
20140243260
Chimeric fibroblast growth factor 23 proteins and methods of use
The present invention relates to an isolated chimeric protein. The isolated chimeric protein includes an n-terminus coupled to a c-terminus, where the n-terminus includes an n-terminal portion from a fibroblast growth factor (“fgf”) 23 molecule and the c-terminus includes a c-terminal portion from an fgf19 molecule.
08/28/14
20140242701
Chimeric antigen receptor
Provided are a chimeric antigen receptor comprising an extracellular domain capable of binding to an antigen, a transmembrane domain and at least one intracellular domain, the chimeric antigen receptor being characterized in that an intracellular domain of a glucocorticoid-induced tumor necrosis factor receptor (gitr) is contained as the intracellular domain; a nucleic acid encoding the chimeric antigen receptor; a cell expressing the chimeric antigen receptor; and a method for producing the cell.. .
08/28/14
20140242673
Chemically defined culture medium for fermentation to produce succinic acid and application thereof
This invention belongs to the technical field of industrial microorganism fermentation and relates to a type of chemical defined medium used for succinic acid production by fermentation and its application. The chemical defined medium of this invention used for succinic acid production by fermentation includes conventional compositions and critical growth factor compositions.
08/28/14
20140242616
Free ngal as a biomarker for cancer
Uncomplexed neutrophil gelatinase associated lipocalin (ngal) is present at increased levels in individuals with atypical ductal hyperplasia (adh), a major risk factor for future breast cancer development; in individuals that have ovarian cancer; and in individuals that have breast cancer, both invasive and noninvasive. Accordingly, the present invention is directed to measuring uncomplexed ngal levels in urine as a primary screen to determine if an individual is either at risk of developing, or has developed cancer, e.g., cancer of epithelial origin including breast and ovarian cancer..
08/28/14
20140242580
Method for predicting response or prognosis of lung adenocarcinoma with egfr-activating mutations
The invention provides a method for predicting the response of an egfr-activating mutant subject suffering from a lung adenocarcinoma and receiving treatment with epidermal growth factor receptor tyrosine kinase inhibitor (egfr-tki) and a method for predicting prognosis in an egfr-activating mutant subject suffering from a lung adenocarcinoma and receiving treatment with egfr-tki. In the methods of the invention, clustered genomic alterations in specific chromosomes (in particular chromosomes 5p, 7p, 8q or 14q) are determined as a tool for predicting the response or prognosis..
08/28/14
20140242135
Compositions for inhibition of insect sensing
In one aspect, the invention relates to chemical modulators of insect olfactory receptors. In particular, compounds and compositions are provided that can inhibit sensory (e.g., host targeting) functions in airborne insects such as mosquitos.
08/28/14
20140242069
Krt19 stabilizing her2 and use thereof
Provided is a method of decreasing the stability of her2 (human epidermal growth factor receptor 2) in a cell or individual comprising administering an effective amount of an expression or activity inhibitor of krt19 (cytokeratin 19) to the cell or individual.. .
08/28/14
20140242067
Treatment of central nervous system disorders by intranasal administration of immunoglobulin g
The present invention provides, among other aspects, methods and compositions for treating a central nervous system (cns) disorder by delivering a therapeutically effective amount of a composition of pooled human immunoglobulin g (igg) to the brain via intranasal administration of the composition directly to the olfactory epithelium of the nasal cavity. In particular, methods and compositions for treating alzheimer's disease are provided..
08/28/14
20140242057
Conjugated factor viii molecules
The present invention relates to b-domain truncated factor viii molecules with a modified circulatory half life, said molecule being covalently conjugated with a hydrophilic polymer. The invention furthermore relates to methods for obtaining such molecules as well as use of such molecules..
08/28/14
20140240914
Fixed interconnect toptlogy for implementing a virtual backplane in a computing rack for field replaceable units
A system for the management of rack-mounted field replaceable units (frus) that affords the enhanced availability and serviceability of frus provided by blade-based systems but in a manner that accommodates different types of frus (e.g., in relation to form factors, functionality, power and cooling requirements, and/or the like) installed within a rack or cabinet.. .
08/28/14
20140240909
Adapter facilitating blind-mate electrical connection of field replaceable units with virtual backplane of computing rack
A system for the management of rack-mounted field replaceable units (frus) that affords the enhanced availability and serviceability of frus provided by blade-based systems but in a manner that accommodates different types of frus (e.g., in relation to form factors, functionality, power and cooling requirements, and/or the like) installed within a rack or cabinet.. .
08/28/14
20140240592
Small form factor pluggable unit used as a video signal conversion device
The present disclosure relates to devices comprising small form factor pluggable units (sfp) having connectors for receiving and sending signals and a processor for converting the received signals prior to sending the converted signals. Received or sent signals may comprise video signals in various analog or digital formats.
08/28/14
20140240529
Thin form factor computational array cameras and modular array cameras
Systems and methods in accordance with embodiments of the invention implement modular array cameras using sub-array modules. In one embodiment, an x×y sub-array module includes: an x×y arrangement of focal planes, where x and y are each greater than or equal to 1; and an x×y arrangement of lens stacks, the x×y arrangement of lens stacks being disposed relative to the x×y arrangement of focal planes so as to form an x×y arrangement of cameras, where each lens stack has a field of view that is shifted with respect to the field-of-views of each other lens stack so that each shift includes a sub-pixel shifted view of the scene; and image data output circuitry that is configured to output image data from the x×y sub-array module that can be aggregated with image data from other sub-array modules so that an image of the scene can be constructed..
08/28/14
20140240528
Thin form factor computational array cameras and modular array cameras
Systems and methods in accordance with embodiments of the invention implement one-dimensional array cameras, as well as modular array cameras using sub-array modules. In one embodiment, a 1×n array camera module includes: a 1×n arrangement of focal planes, where n is greater than or equal to 2, each focal plane includes a plurality of rows of pixels that also form a plurality of columns of pixels, and each focal plane not including pixels from another focal plane; and a 1×n arrangement of lens stacks, the arrangement of lens stacks being disposed relative to the arrangement of focal planes so as to form a 1×n arrangement of cameras, each configured to independently capture an image of a scene, where each lens stack has a field of view that is shifted with respect to that of each other lens stack so that each shift includes a sub-pixel shifted view of the scene..
08/28/14
20140240512
Time spaced infrared image enhancement
Techniques using small form factor infrared imaging modules are disclosed. An imaging system may include visible spectrum imaging modules, infrared imaging modules, and other modules to interface with a user and/or a monitoring system.
08/28/14
20140239718
Power delivery to rack-mounted field replaceable units using ac and/or dc input power sources
A system for the management of rack-mounted field replaceable units (frus) that affords the enhanced availability and serviceability of frus provided by blade-based systems but in a manner that accommodates different types of frus (e.g., in relation to form factors, functionality, power and cooling requirements, and/or the like) installed within a rack or cabinet.. .
08/28/14
20140239086
Interactive entertainment apparatus and system and a method of interacting with water to provide audio, visual, olfactory, gustatory or tactile effect
An interactive entertainment apparatus and system and a method of interacting with water to provide audio, visual, olfactory, gustatory and/or tactile effects are provided. In one embodiment, the apparatus and system comprise one or more imagery multilevel channel communications input and/or multilevel channel communications output device(s), one or more sound multilevel channel communications input and/or multilevel channel communications output device(s); one or more camera and/or motion multilevel channel communications input and/or multilevel channel communications input device(s); one or more nozzle assemblies for spraying and/or emitting liquid and/or vapour and/or gas that can produce lively and entertaining liquid and/or vapour and/or gas screen and/or middle drop(s)/screen(s)and/or other arena-like and/or skyscreen-like arrangement(s) located at or near the centre(s) or focal zone(s) of the theatrical arrangement(s) for the entertainment apparatus and system, on to which liquid and/or vapour and/or gas screen and/or contour arrangement(s) can be projected and/or augmented by harmonized and/or sychronized light and/or laser source for entertaining lighting and/or laser shows; one or more sound generating and/or broadcasting device(s); one or more light and/or laser source(s); one or more tactile stimulus multilevel channel communications input and/or multilevel channel communications output device(s) and/or one or more heating and/or cooling device(s) adapted to provide a tactile sensation of three-dimensional movement(s), motion(s) and/or tilting and/or temperature alteration(s) or variation(s); one or more olfactory stimulus multilevel channel communications input and/or multilevel channel communications output device(s); one or more gustatory stimulus multilevel channel communications input and/or multilevel channel communications output device(s), according to the occurrence of one or more events (random, reconfigurable and/or pre-set) and/or the multilevel channel communications input from one or more user-interface device(s), when activated automatically or on the demand(s), option(s) and/or desire(s) of the user(s); one or more device(s) modulator and/or controller which modulates and/or controls one or more of the above devices and/or one or more parameters of the features of the invention; and one or more interactive microprocessing, computing and/or data-transmission system(s) and/or device(s) to capture, animate, digitize, vary, modify and co-ordinate light emissions, sound or musical note and/or tune broadcasting, tactile stimulus multilevel channel communications input and/or multilevel channel communications output, olfactory stimulus multilevel channel communications input and/or multilevel channel communications output, gustatory stimulus multilevel channel communications input and/or multilevel channel communications output, and/or dancing water trajectories with random, reconfigurable and/or pre-set motions and/or sound multilevel channel communications inputs and/or multilevel channel communications output, produced and/or caused by and/or through interaction of human, animal and/or objects, into control multilevel channel communications inputs, data and/or signals delivered automatically or on the demand(s), option(s) and/or desire(s) of the user(s) to one or more device controllers for controlling the trajectory(ies) of liquid and/or vapour and/or gas emitted from the nozzle assembly(ies), the sound generating and/or broadcasting, the mood, soft or hard lighting changes and/or laser renditions to produce life-like, integrated, artistic and featured entertaining performances automatically or on the demand(s), option(s) and/or desire(s) of the user(s)..
08/28/14
20140238883
Dose dispensing containers
Internally pierced formed blisters containing fluid compositions for use in devices to produce a spray or mist delivery of the compositions include internal piercing nozzles that can have significantly reduced channel volume to increase pressure of the fluid forced through the nozzle and provide finer control of spray geometry. The piercing nozzles are configured to deliver the contents of the blister to the central nervous system through the nasal olfactory epithelium..
08/21/14
20140235829
Compositions and methods for regulation of tumor necrosis factor-alpha
The present invention relates to compositions and methods relating to an interleukin 18-inducible cytokine termed tumor necrosis factor-alpha inducing factor (taif) or interleukin-32 (il-32). In particular, the present invention provides compositions and methods for treating autoimmune diseases and cancer, in part by regulation of tumor necrosis factor-alpha expression..
08/21/14
20140235539
Composite collagen sponge and preparation method thereof
The present invention discloses a composite collagen sponge and the preparation method thereof. The composite collagen sponge comprises collagen, cell growth factors, and a protecting agent, and has a water absorption capacity of more than 52 times.
08/21/14
20140235538
Stabilized insulin-like growth factor polypeptides
The invention relates to stabilized polypeptides having an igf-1 or igf-2 sequence and an e-peptide sequence, where the natural physiological cleavage of the e-peptide from the igf is prevented.. .
08/21/14
20140235494
Methods, kits and computer program products using hepatocellular carcinoma (hcc) biomarkers
Methods of determining the presence or risk of liver disease or other diseases in a subject include measuring a level of a saccharide selected from n-acetylneuraminic acid, n-acetylglucosamine, n-acetylgalactosamine, or a combination thereof on one or more glycosylated proteins and the total amount of alpha-fetoprotein in a biological sample from the subject. Glycosylated proteins include but are not limited to vascular endothelial growth factor, lymphatic vessel endothelial hyaluronan receptor, e-cadherin, alpha 1 acid glycoprotein, glypican-3, galectin-3, and any combination thereof.
08/21/14
20140234971
Induction of hemogenic endothelium from pluripotent stem cells
Described herein are methods and related compositions for inducing differentiation of human pluripotent stem cells (hpscs) into hemogenic endothelium with pan-myeloid potential or restricted potential, by forced expression in the hpscs of a combination of transcription factors as described herein.. .
08/21/14
20140234964
Novel methods and formulations for orthopedic cell therapy
Aspects of the present invention include methods and compositions related to the production and use of clonal lineages of embryonic progenitor cell lines derived from differentiating cultures of primordial stem cells, in particular, said methods and compositions relate to methods of differentiating cells in the presence of bmp family mambeis of growth factors and the applications of said cell lines in the treatment of degenerative orthopedic diseases such as osteoarthritis,. .
08/21/14
20140234851
Modular extracellular sensor architecture for cell-based biosensors
The present invention provides modular extracellular sensors, nucleic acids encoding such sensors, and cells expressing such sensors, and methods of employing such sensors and cells for detecting extracellular ligands. In certain embodiments, the extracellular sensors comprise a ligand binding domain, a transmembrane domain, a protease domain, a protease cleavage site, and a transcription factor.
08/21/14
20140234817
Systems and methods for helping students achieve academic success and persist through college
Described herein are systems and methods for causing behavior modification of a large population of students by providing electronic messages, referred to as nudges, to the students. A program of nudges is assigned to each student based on collected background information and feedback from the students and/or third parties.
08/21/14
20140234341
Acute hepatic insufficiency depressant and method for evaluating drug efficacy thereof
The present invention provides a therapeutic agent for acute liver failure containing a hepatocyte growth factor (hgf), particularly an agent for treating fulminant hepatitis or late onset hepatic failure or suppression of progression of acute liver failure without hepatic coma to fulminant hepatitis or late onset hepatic failure. The present invention also provides a method for evaluating the efficacy of hgf including measuring the amount of α-fetoprotein (liver regeneration biomarker) and/or soluble fas (anti-apoptotic biomarker) in a sample obtained from a liver injury patient administered with hgf..
08/21/14
20140234328
Use of c-met protein for predicting the efficacy of anti-hepatocyte growth factor ("hgf") antibodies in esophageal and gastric cancer patients
The present invention relates to use of the human met receptor (also known as “c-met”) for predicting the efficacy of inhibitors of the hgf-met pathway, and in particular, anti-hgf antibodies, in the treatment of esophageal and gastric cancer patients. The present invention also relates to methods and kits for predicting the usefulness of anti-hgf antibodies in the treatment of esophageal and gastric cancer..
08/21/14
20140234314
Antibodies against epidermal growth factor receptor (egfr) and uses thereof
Anti-egfr antibodies, therapeutic compositions comprising combinations of anti-egfr antibodies, as well as methods for using such antibodies and compositions to treat egfr-related disorders (e.g., cancers), are disclosed.. .
08/21/14
20140234308
Treatment of breast cancer with companion diagnostic
Despite advances in therapy, breast cancer remains the most common malignancy in women. Of particular concern is the aggressive triple negative subtype that lacks the brca1 mutation, estrogen receptor, and epidermal growth factor type 2 receptor (her-2/neu), which accounts for approximately half of all breast cancer deaths.
08/21/14
20140234304
Human tissue factor antibody and uses thereof
The invention relates to a humanized form of an antibody capable of preventing tissue factor (coagulation factor f3) signaling but which does not interfere with factor vii binding or fx binding to tissue factor and does not prolong coagulation time. The antibody of the invention is useful in treating conditions, such as tumor progression, in which the associated cells express tissue factor and tissue factor signaling occurs..
08/21/14
20140234297
Antibody constant domain regions and uses thereof
The invention provides recombinant protein (e.g., a recombinant antibody or soluble receptor) having (i) a binding domain capable of specific binding to an epitope (for example an antibody variable domains, a receptor, a growth factor, a cytokine, or a fragment of any of the foregoing which is capable of specifically binding the desired epitope) and (ii) an effector domain comprising a constant domain region which is derived from immunoglobulin of a first species which is a companion mammal, e.g. Dog, cat, or horse, having engineered substitutions at one or more positions and having an altered interaction with one or more fcrs or other ligands, and optionally enhanced effector function, relative to the parent constant domain region..
08/21/14
20140234294
Fibroblast growth factor receptor-derived peptides binding to ncam
The present invention relates to the use of peptides that are capable of binding to, and modulating the activity of ncam. The peptides are peptide fragments of fgfrs.
08/21/14
20140234290
Modified factor x polypeptides and uses thereof
Modified therapeutic proteins are provided. In particular modified factor x polypeptides, which includes the factor x zymogen, factor xa and other forms of factor x, and uses thereof are provided..
08/21/14
20140234266
Cultured hematopoietic stem cells and method for expansion and analysis thereof
Hematopoietic stem cells and methods for ex vivo expansion of hematopoietic stem cells are provided. The methods comprise culturing the cells in a media containing an effective amount insulin-like growth factor (igf), fibroblast growth factor (fgf), thrombopoietin (tpo), and stem cell factor (scf), under conditions sufficient for expansion of said cells.


Popular terms: [SEARCH]



Follow us on Twitter
twitter icon@FreshPatents

###

This listing is a sample listing of patent applications related to Factor for is only meant as a recent sample of applications filed, not a comprehensive history. There may be associated servicemarks and trademarks related to these patents. Please check with patent attorney if you need further assistance or plan to use for business purposes. This patent data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Factor with additional patents listed. Browse our RSS directory or Search for other possible listings.
     SHARE
  
         


FreshNews promo



0.3022

4085

2 - 1 - 80